Wall Street's major averages took home gains on Friday, with the S&P 500 reclaiming the 6,000 level for the first time since late February, as sentiment was boosted by a strong May jobs report.

BMY is looking to expand its pipeline/portfolio as the legacy portfolio is being adversely impacted due to continued generic ...

The PD-(L)1xVEGF field had a roller coaster week marked by an imperfect readout and a potentially $11 billion deal. | The PD- ...

Bristol-Myers Squibb and BioNTech announced a major deal worth up to $11 billion in early June. Click here to find out why I ...

Princeton: BioNTech SE and Bristol Myers Squibb have announced that the companies have entered into an agreement for the ...

Bristol Myers and BioNTech are teaming up to develop and commercialize BNT327, a cancer therapy with blockbuster ambition.

Two drugs. Two strategies. One industry in the middle of a rewiring.

Marketed as BNT327, the PD-L1xVEGF-A bispecific antibody has the potential to become what the involved parties believe is a ...

Sanofi and BMS paid big money for rare disease and cancer assets, while Regeneron got in the obesity game; AstraZeneca, Gilead and Amgen shone at ASCO; RFK Jr. and the CDC appeared to disagree over ...

Bristol-Myers Squibb has teamed up with BioNTech to co-develop a bispecific antibody, BNT327, targeting multiple solid tumors ...

BMS will co-develop and co-commercialize BioNTech’s bispecific antibody BNT327 for solid tumors in a deal worth up to $11.1B ...